Abstract
The tumor suppressor gene p53 is a potent transcriptional regulator of genes which are involved in many cellular activities including cell cycle arrest, apoptosis, and angiogenesis. Recent studies have demonstrated that the activation of the transcriptional factor nuclear factor κB (NF-κB) plays an essential role in preventing apoptotic cell death. In this study, to better understand the mechanism reponsible for the p53-mediated apoptosis, the effect of wild-type p53 (wt-p53) gene transfer on nuclear expression of NF-κB was determined in human colon cancer cell lines. A Western blot analysis of nuclear extracts demonstrated that NF-κB protein levels in the nuclei were suppressed by the transient expression of the wt-p53 in a dose-dependent manner. Transduced wt-p53 expression increased the cytoplasmic expression of IκBα as well as its binding ability to NF-κB, thus markedly reducing the amount of NF-κB that translocated to the nucleus. The decrease in nuclear NF-κB protein correlated with the decreased NF-κB constitutive activity measured by electrophoretic mobility shift assay. Furthermore, parental cells transfected with NF-κB were better protected from cell death induced by the wt-p53 gene transfer. We also found that the wt-p53 gene transfer was synergistic with aspirin (acetylsalicylic acid) in inhibiting NF-κB constitutive activity, resulting in enhanced apoptotic cell death. These results suggest that the inhibition of NF-κB activity is a plausible mechanism for apoptosis induced by the wt-p53 gene transfer in human colon cancer cells and that anti-NF-κB reagent aspirin could make these cells more susceptible to apoptosis.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
Abbreviations
- wt-p53:
-
wild-type p53
- NF-κB:
-
nuclear factor κB
- CMV:
-
cytomegalovirus
- MOI:
-
multiplicity of infection
- EMSA:
-
electrophoretic mobility shift assay
- NSAID:
-
nonsteroidal anti-inflammatory drugs
References
Auphan N, DiDonoto JA, Rosette C, Helmberg A and Karin M. . 1995 Science 270: 286–290.
Baldwin Jr AS. . 1996 Annu. Rev. Immunol. 14: 649–681.
Beg AA and Baltimore D. . 1996 Science 274: 782–784.
Beg AA, Finco TS, Nantermet PV and Baldwin Jr AS. . 1993 Mol. Cell. Biol. 13: 3301–3310.
Beg AA, Sha WC, Bronson RT, Ghosh S and Baltimore D. . 1995 Nature 376: 167–170.
Bellas RE, FitzGerald MJ, Fausto N and Sonenshein GE. . 1997 Am. J. Pathol. 151: 891–896.
Bours V, Dejardin E, Goujon-Letawe F, Merville MR and Castronovo V. . 1994 Biocham. Pharmaco. 47: 145–149.
Fujiwara T, Cai DW, Georges RN, Mukhopadhyay T, Grimm EA and Roth JA. . 1994a J. Natl. Cancer Inst. 86: 1458–1462.
Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB and Roth JA. . 1994b Cancer Res. 54: 2287–2291.
Fukazawa T, Fujiwara T, Morimoto Y, Shao J, Nishizaki M, Kadowaki Y, Hizuta A, Owen-Schaub LB, Roth JA and Tanaka N. . 1999 Oncogene 18: 2189–2199.
Giri DK and Aggarwal BB. . 1998 J. Biol. Chem. 273: 14008–14014.
Grilli M, Pizzi M, Memo M and Spano P. . 1996 Science 274: 1383–1385.
Harris CC. . 1996 J. Natl. Cancer Inst. 88: 1442–1455.
Higgins KA, Perez JR, Coleman TA, Dorshkind K, McComas WA, Sarmiento UM, Rosen CA and Narayanan R. . 1993 Proc. Natl. Acad. Sci. USA 99: 9901–9905.
Insel PA. . 1990 The Pharmacological Basis of Therapeutics. Gilman AC, Rall TW, Niers AS and Taylor P (eds).. Pergamon Press: New York pp. 638–681.
Jeremias I, Kupatt C, Baumann B, Herr I, Wirth T and Debatin KM. . 1998 Blood 91: 4624–4630.
Kagawa S, Fujiwara T, Hizuta A, Yasuda T, Zhang WW, Roth JA and Tanaka N. . 1997 Oncogene 15: 1903–1910.
Kochetkova M, Iversen PO, Lopez AF and Shannon MF. . 1997 J. Clin. Invest. 99: 3000–3008.
Kopp E and Ghosh S. . 1994 Science 265: 956–958.
Mukhopadhyay T, Roth JA and Maxwell SA. . 1995 Oncogene 11: 999–1003.
Nakshatri P, Bhat-Nakshatri P, Martin DA, Goulet RJ and Sledge Jr GW. . 1997 Mol. Cell. Biol. 17: 3629–3639.
Ogawa N, Fujiwara T, Kagawa S, Nishizaki M, Morimoto Y, Tanida T, Hizuta A, Yasuda T, Roth JA and Tanaka N. . 1997 Int. J. Cancer 73: 367–370.
Ravi R, Mookerjee B, Ven Hensbergen YV, Bedi GC, Giordano A, El-Deiry WS, Fuchs EJ and Bedi A. . 1998 Cancer Res. 58: 4531–4536.
Raziuddin A, Court D, Sarkar FH, Liu LY, Kung HF and Raziuddin RJ. . 1997 J. Biol. Chem. 272: 15715–15720.
Scheinman RI, Cogswell PC, Lofquist AK, Baldwin Jr AB. . 1995 Science 270: 283–286.
Shao R, Karunagaran D, Zhou BP, Li K, Lo SS, Deng J, Chiao P and Hung MC. . 1997 J. Biol. Chem. 272: 32739–32742.
Shattuck-Brandt RL and Richmond A. . 1997 Cancer Res. 57: 3032–3039.
Shiff SL and Rigas B. . 1997 Gastroenterology 113: 1992–1998.
Stehlik C, Martin R, de Kumabashiri I, Schmid JA, Binder BR and Lipp J. . 1998 J. Exp. Med. 18: 211–216.
Swisher SG, Roth JA, Nemunaitis J, Lawrenc DD, Kem BL, Carrasco CH, Connors DG, El-Naggar A, Fossell F, Glisson BS, Hong WK, Khuri FR, Kurie JM, Lee JJ, Lee JS, Mack M, Merrit JA, Nguyen DM, Nesbitt JC, Perez-Soler R, Pisters KM, Putnam Jr JB, Richli WR, Savin M, Schrump DS, Shin DM, Shulkin A, Walsh GL, Wait J, Weill D and Waugh MK. . 1999 J. Natl. Cancer Inst. 91: 763–771.
Van Antwerp DJ, Martin SJ, Douglas RTK and Verma IM. . 1996 Science 274: 787–789.
Wadgaonkar R, Phelps KM, Haque Z, Williams AJ, Silverman ES and Collins T. . 1999 J. Biol. Chem. 274: 1879–1882.
Wang CY, Mayo MW and Baldwin Jr JS. . 1996 Science 274: 784–787.
Wang CY, Mayo MW and Korneluk RG. . 1998 Science 281: 1680–1683.
Webster GA and Perkins ND. . 1999 Mol. Cell. Biol. 19: 3485–3495.
Wong HR, Ryan M and Wispe JR. . 1997 J. Clin. Invest. 99: 2423–2428.
Wu MX, Ao Z, Prasad KVS, Wu R and Schlossman SF. . 1998 Science 281: 998–1001.
Yamagishi N, Miyakoshi J and Takebe H. . 1997 Int. J. Radiat. Biol. 72: 157–162.
Acknowledgements
We thank Dr Takashi Okamoto (Department of Molecular Genetics, Nagoya City University Medical School) for helpful discussions. We also thank Tohru Tanida and Kyoko Nasu for their technical support. This work was supported in part by grants from the Ministry of Education, Science, and Culture, Japan, and by grants from the Ministry of Health and Welfare, Japan (Health Sciences Research Grants [Research on Human Genome and Gene Therapy]).
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Shao, J., Fujiwara, T., Kadowaki, Y. et al. Overexpression of the wild-type p53 gene inhibits NF-κB activity and synergizes with aspirin to induce apoptosis in human colon cancer cells. Oncogene 19, 726–736 (2000). https://doi.org/10.1038/sj.onc.1203383
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.onc.1203383
Keywords
This article is cited by
-
FX1, a BCL6 inhibitor, reactivates BCL6 target genes and suppresses HTLV-1-infected T cells
Investigational New Drugs (2022)
-
P53 vs NF-κB: the role of nuclear factor-kappa B in the regulation of p53 activity and vice versa
Cellular and Molecular Life Sciences (2020)
-
Up-regulation of Siah1 by ethanol triggers apoptosis in neural crest cells through p38 MAPK-mediated activation of p53 signaling pathway
Archives of Toxicology (2017)
-
The aspirin-induced long non-coding RNA OLA1P2 blocks phosphorylated STAT3 homodimer formation
Genome Biology (2016)
-
p53 predominantly regulates IL-6 production and suppresses synovial inflammation in fibroblast-like synoviocytes and adjuvant-induced arthritis
Arthritis Research & Therapy (2016)